US pharmaceuticals company Pfizer is to increase prices on 41 drugs in the new year. The majority of the drugs will see a 5% rise, with three only changing by 3% and one facing a 9% increase. For example, a plan to require direct-to-consumer drug advertisements to include the list prices of drugs drew concerns that it may cause confusion among consumers, including the risk of sticker shock that could scare patients out of taking their drugs. The specific drugs have not been confirmed but the number will make up 10% of the firm's portfolio, while a spokesperson said higher rebates and discounts to insurance companies are expected to offset the cost increase. In an interview with Bloomberg News, Pfizer's chief executive, Ian Read, said: "We believe that we can deliver better value for patients through our pricing strategy than other payers can, which has led us to seek out
US pharmaceuticals company Pfizer is to increase prices on 41 drugs in the new year. The majority of the drugs will see a 5% rise, with three only changing by 3% and one facing a 9% increase. The specific drugs have not been confirmed but the number will make up 10% of the firm's portfolio, while a spokesperson said higher rebates and discounts to insurance companies are expected to offset the cost increase. In an interview with Bloomberg News, Pfizer's chief executive, Ian Read, said: "We believe that we can deliver better value for patients through our pricing strategy than other payers can, which has led us to seek out